In a peptide market dominated by research-grade compounds and regulatory gray areas, tesamorelin stands alone: it is the only growth hormone releasing peptide with full FDA approval. Approved for HIV-associated lipodystrophy — the visceral fat accumulation that antiretroviral therapy can cause — tesamorelin stimulates endogenous growth hormone release through a legitimate, prescribed pathway. For men who want the GH-boosting effects of secretagogue peptides without the legal and quality uncertainties of the research market, tesamorelin is the only option with a regulatory stamp.
⚡ Key Takeaway
Tesamorelin is the only FDA-approved growth hormone releasing peptide, approved for HIV-associated lipodystrophy. It stimulates endogenous GH production, reduces visceral fat, and increases skeletal muscle area. Off-label prescribing for body composition is legally possible but insurance coverage is limited.
What Tesamorelin Does
Tesamorelin is a synthetic analog of growth hormone releasing hormone (GHRH) that stimulates the pituitary to produce and release growth hormone. Unlike exogenous GH injections that bypass the body’s regulatory feedback, tesamorelin works within the endogenous system — your pituitary still controls the final output, which means you get GH elevation without the supraphysiologic peaks that cause exogenous GH’s side effects.
In clinical trials for its approved indication, tesamorelin produced measurable reductions in visceral adipose tissue (the deep abdominal fat that wraps around organs) and increases in skeletal muscle area and density. The body composition shift — less visceral fat, more muscle — is what drew the performance community’s attention, even though the approved indication is specific to HIV-associated lipodystrophy.
Tesamorelin vs Gray-Market Secretagogues
The comparison to CJC-1295 + Ipamorelin is inevitable. Both approaches stimulate endogenous GH. Tesamorelin offers pharmaceutical-grade purity, standardized dosing, physician oversight, and legal clarity. CJC-1295 + Ipamorelin offers lower cost, no prescription requirement, and arguably a more targeted secretagogue mechanism (Ipamorelin’s selectivity for GH over cortisol/prolactin).
The trade-off is real: tesamorelin costs significantly more than research-grade secretagogues, insurance rarely covers off-label use, and accessing it requires a prescribing physician willing to write for an off-label indication. For men whose priority is verified quality and legal standing, the premium is justified. For men whose priority is economics, the research-grade stack remains the more accessible option.
The Visceral Fat Angle
Visceral fat is the most metabolically dangerous fat depot. Unlike subcutaneous fat (the fat you can pinch), visceral fat is hormonally active — it produces inflammatory cytokines, disrupts insulin signaling, and is strongly correlated with cardiovascular disease, type 2 diabetes, and metabolic syndrome. Men carry a disproportionate share of visceral fat compared to women, and it is the fat depot that responds least to standard dieting.
Tesamorelin’s demonstrated ability to reduce visceral fat specifically — not just total body weight — addresses the highest-risk fat depot rather than treating all fat as equivalent. For men with significant visceral fat accumulation (the firm, distended midsection rather than soft subcutaneous tissue), tesamorelin targets the fat that matters most for both health outcomes and the physical appearance of midsection leanness.